Himawari (satellites)

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Retrieved on: 
Thursday, April 4, 2024
CGM, Consultant, Negotiation, Conference, Growth, Data analysis, HIV, Himawari (satellites), Diabetes, World Health Organization, Acquisition, American depositary receipt, Diagnosis of HIV/AIDS, Units of paper quantity, Clinical trial, Injection, Balance sheet, Waveform, Pharmaceutical industry

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Key Points: 
  • DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
  • We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
  • The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
  • Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:

One Health Direct Introduces Maternity Products To Better Serve DME Partner's Patients

Retrieved on: 
Monday, March 4, 2024
Woman, Care Act 2014, Education, Suction, Himawari (satellites), OHD, Affordable Care Act, Communication, Diabetes, Mother, Patient, Child, Massage, DME, Insurance

DUNEDIN, Fla., March 4, 2024 /PRNewswire/ -- One Health Direct (OHD) announced the expansion of its patient engagement, operational support, and product facilitation services to include a range of maternity products.

Key Points: 
  • DUNEDIN, Fla., March 4, 2024 /PRNewswire/ -- One Health Direct (OHD) announced the expansion of its patient engagement, operational support, and product facilitation services to include a range of maternity products.
  • OHD has recognized the importance of patient education and eligibility with other DME products and will now provide maternity products for their DME partner's patients.
  • Expecting mothers are often unaware of the medical benefits, ease of availability and eligibility of maternity products.
  • New and expecting mothers are often unaware of the medical benefits, ease of availability, and requirements for coverage eligibility of certain maternity products and supplies.

Helmsley Charitable Trust Awards Over $12 Million to Projects Aimed at Helping People With Type 1 Diabetes Safely Incorporate Exercise Into Their Daily Lives

Retrieved on: 
Tuesday, February 13, 2024
Technology, Research, Sports, Diabetes, Managed Care, General Health, Data Analytics, General Sports, Pharmaceutical, Medical Devices, Health Technology, Fitness & Nutrition, Clinical Trials, Professional Services, Artificial Intelligence, Biotechnology, Philanthropy, Software, Health, Foundation, Science, University, OpenAPS, Algorithm, University of Pennsylvania, University College Dublin, Doctor of Philosophy, Multimedia, Education, FDA, Himawari (satellites), Quality of life, AID, Charitable trust, Menstruation, Exercise, CCRA, MBA, Risk, Stanford University, University of Trento, Safety, RFP, Helmsley, Hypoglycemia, Insulin, MPH, York University, Knowledge, Clinical trial, Trial of the century

Today, The Leona M. and Harry B. Helmsley Charitable Trust announces seven new grants to support research aimed at helping people with type 1 diabetes (T1D) more safely incorporate exercise into their lives.

Key Points: 
  • Today, The Leona M. and Harry B. Helmsley Charitable Trust announces seven new grants to support research aimed at helping people with type 1 diabetes (T1D) more safely incorporate exercise into their lives.
  • More research and solutions are urgently needed to ease the burden of exercise with T1D management.
  • The data sets are publicly available through Vivli, a data-sharing platform that hosts information on a variety of health conditions.
  • The study will provide practical advice and a potentially cost-effective solution for people with T1D engaging in exercise.

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Retrieved on: 
Monday, February 12, 2024
Software, Mobile, Wireless, Professional Services, Consumer Electronics, Apps, Applications, Medical Devices, Technology, Health Technology, Health Insurance, Insurance, Health, Diabetes, Blood glucose monitoring, MAC, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Retrieved on: 
Monday, February 12, 2024
Blood glucose monitoring, MAC, Diabetes, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Automotive Central Gateway Module Market to grow by USD 1.15 billion from 2022 to 2027, Increasing government support to promote EVs to boost the growth - Technavio

Retrieved on: 
Monday, February 5, 2024
Aptiv, Growth, Electronics, Internet of things, Infineon Technologies, CGM, ICE, NXP Semiconductors, ESO, Government, LIN, Continental AG, USD, Climate change, Safety, Challenge, STMicroelectronics, EV, Robert Bosch GmbH, Texas Instruments, Himawari (satellites), Communication, Lear Corporation, Écu, TDK, Risk, Semiconductor industry, EVS, Hitachi

Increasing government support to promote EVs is a key factor driving growth.

Key Points: 
  • Increasing government support to promote EVs is a key factor driving growth.
  • Technavio has segmented the market based on application (passenger cars and commercial vehicles), type (LIN central gateway module, CAN central gateway module, and ethernet central gateway module), and Geography (APAC, North America, Europe, South America, and Middle East and Africa).
  • The automotive central gateway module serves as a critical component in modern automotive electronics, facilitating vehicle connectivity and communication within in-vehicle networks.
  • Overall, the central gateway module enhances vehicle electronics integration and provides automotive connectivity solutions for advanced automotive systems.

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

Retrieved on: 
Monday, November 13, 2023
Diet, Longevity, Insulin, Hypoglycemia, American Diabetes Association, Diagnosis, CGM, Insurance, Trust, CMS, Evidence, Diabetes, Growth, Doctor of Philosophy, Medicare, Himawari (satellites), Prediabetes, Clinical chemistry, Letter, BGM, Environment, Management, Medical device, Pharmaceutical industry

Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.

Key Points: 
  • Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.
  • In recent years, the diabetes market has experienced a significant transformation, driven by the growth of continuous glucose monitoring (CGM).
  • This was the first update to the guidelines since 2011 and included major shifts in clinical thinking.
  • In the last shareholder update, we had recognized that this would raise the regulatory bar for any non-invasive glucose sensor performance.

ŌURA Reaches Milestone of 600+ Partnerships and Integrations as It Builds a Large-Scale Ecosystem

Retrieved on: 
Thursday, November 30, 2023
Software, Biometrics, Biotechnology, General Health, Health, Health Technology, Technology, Other Health, Stress management, Woman, Behavior, Flexible, Entrepreneurship, CGM, Algorithm, Ecosystem, Cycle track, Dashboard, FSA, Growth, API, IOS, Temperature, Health savings account, Abdominal obesity, Flexible spending account, Tag, HDL, Fertility, Menopause, Oura Health, Life, Science, Meditation, Chart, Natural Cycles, Menstrual cycle, Obstetrics, DSM-IV codes, PCOS, Skin temperature, Community, Blood, Currency strap, Partnership, Himawari (satellites), Education, Hypertension, Research, Apple Watch, Learning, HSA, Pregnancy, Metabolism, FDA, Chronotype, Diary, Ready, Set, PrEP, Mindfulness, Thrive Global, Phosphorus, Mobile phone, Birth control, Pharmaceutical industry, Nursing, Medical device, Sleep, Oura, Headspace, Activity, Noom, Strava

We’ve been steadily building a strong partnership ecosystem and adding world-class features into the ŌURA experience,” said Tom Hale, CEO.

Key Points: 
  • We’ve been steadily building a strong partnership ecosystem and adding world-class features into the ŌURA experience,” said Tom Hale, CEO.
  • “ŌURA is becoming an iconic, global brand that is changing the way we think about long-term health and healthspan.
  • ŌURA is doubling down in specific focus areas with partners across several sectors including women’s health, metabolic health, behavioral health, and fitness and lifestyle.
  • These integrations represent a significant portion of new ŌURA members; additionally, ŌURA members who use Natural Cycles are the highest retaining of all ŌURA cohorts.

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
Monday, December 11, 2023
Epidemiology, AID, Standard of care, Infection, PPC, Gestational diabetes, Diagnosis, CVD, Disability, Doctor of Philosophy, Mental health, Abridgement, Prediabetes, Diabetes, Knowledge, Webcast, NAFLD, RSV, Endocrinology, Fatty liver disease, Kidney disease, Cardiovascular disease, Fracture, Moyamoya disease, Society, Physician, Public, Hypoglycemia, Waist, Practitioner, PAD, Risk, Pharmacist, GIP, C-peptide, Artificial intelligence, Immunization, Conditional sentence, Section 4, Body mass index, Himawari (satellites), Classification, The Obesity Society, American Diabetes Association, Vaccine, Obesity, American College, Heart failure, COVID-19, Dietary supplement, Nursing, Landscape maintenance, Pharmaceutical industry, Medical device, Dentistry, MD

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

eddii, a gamified diabetes app, has now launched in the states of Arkansas, Louisiana, Nebraska, and Kansas

Retrieved on: 
Monday, November 13, 2023
RCT, T1D, Android, Insulin, MMV, Randomized controlled trial, Food, Clinical trial, CGM, Mitch Kapor, Google Play, Health, App Store (iOS/iPadOS), Blood, Partnership, Doctor of Philosophy, TIR, Parent, API, Himawari (satellites), Dexcom, Diabetes, IOS, Medical device, Online shopping

LITTLE ROCK, Ark., Nov. 13, 2023 /PRNewswire-PRWeb/ -- eddii, a new diabetes management interface that gamifies real-time glucose data, is pleased to announce its launch in the states of Arkansas, Louisiana, Nebraska and Kansas, as it proceeds with its plans to expand nationwide.

Key Points: 
  • By launching in these select states in the South and Midwest of the United States, eddii plans to increase access to diabetes care for families living in rural areas of the country.
  • eddii is focusing on children living with diabetes and their families, with plans to expand into the adult market very soon.
  • With eddii, children and their families take managing diabetes to a different level, motivating them to stick to healthy routines.
  • That way, parents can have a reliable interface at the tip of their hands to manage their child's diabetes."